Vital KSK HoldingsTSE:3151 -0.32%70 Return-on-Tangible-Equity is 5.52% as of Mar. 2026, which is 2% above its 10-year median of 5.39. GuruFocus rates TSE:3151 with a GF Score™ of 70/100 and a GF Value™ of 円1,324.91 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 111 Medical Distribution companies, Vital KSK Holdings ranks worse than 62.16% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vital KSK Holdings's annualized net income for the quarter that ended in Mar. 2026 was 円5,892 Mil. Vital KSK Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円106,671 Mil. Therefore, Vital KSK Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.52%.
The historical rank and industry rank for Vital KSK Holdings's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3151'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.23 Med: 5.39 Max: 7.22
Current: 7.1
During the past 13 years, Vital KSK Holdings's highest Return-on-Tangible-Equity was 7.22%. The lowest was 1.23%. And the median was 5.39%.
TSE:3151's Return-on-Tangible-Equity is ranked worse than 62.16% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs TSE:3151: 7.10
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vital KSK Holdings Return-on-Tangible-Equity Related Terms
Vital KSK Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vital KSK Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3151 vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Vital KSK Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vital KSK Holdings Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Vital KSK Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vital KSK Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.52% mean?
Vital KSK Holdings (TSE:3151) has a Return-on-Tangible-Equity of 5.52% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vital KSK Holdings and its competitors. This is near median its historical median of 5.39. Over the past decade, Vital KSK Holdings' Return-on-Tangible-Equity has ranged from 1.23 to 7.22. According to the industry distribution chart, Vital KSK Holdings ranks #69 out of 111 companies in the Medical Distribution industry, placing it in the top 62.2%.
Is Vital KSK Holdings' Return-on-Tangible-Equity too high?
Vital KSK Holdings' current Return-on-Tangible-Equity of 5.52% is near median its 10-year median of 5.39. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 7.22. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Vital KSK Holdings' value of 5.52% is 37.3% below this industry median. Based on the distribution chart, Vital KSK Holdings ranks #69 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Vital KSK Holdings has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vital KSK Holdings' Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Vital KSK Holdings ranks #69 out of 111 companies for Return-on-Tangible-Equity. This places Vital KSK Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Vital KSK Holdings' value of 5.52% is 37.3% below this benchmark. Historically, Vital KSK Holdings' own Return-on-Tangible-Equity has ranged from 1.23 to 7.22 over the past decade. While the company's 10-year median is 5.39 vs. the industry median of 8.81, Vital KSK Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vital KSK Holdings's current Return-on-Tangible-Equity of 5.52% is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vital KSK Holdings and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vital KSK Holdings's current Return-on-Tangible-Equity is 5.52%, which is near median its own 10-year median of 5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vital KSK Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vital KSK Holdings (TSE:3151) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,324.91, compared to a current price of 円1,560.00 — trading 17.7% above its estimated fair value. The current Return-on-Tangible-Equity is 5.52%, which is near median its 10-year median of 5.39 and 37.3% below the Medical Distribution industry median of 8.81. Vital KSK Holdings' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vital KSK Holdings (TSE:3151), the current Return-on-Tangible-Equity is 5.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vital KSK Holdings (TSE:3151) Overvalued in 2026?
Based on GuruFocus' analysis, Vital KSK Holdings stock appears to be overvalued.
The current stock price of 円1,560.00 is trading 17.7% above its estimated GF Value™ of 円1,324.91.
GuruFocus considers Vital KSK Holdings to be Modestly Overvalued.
Key valuation signals for TSE:3151:
Return-on-Tangible-Equity: 5.52% (near median its 10-year median of 5.39)
GF Value™: 円1,324.91 vs. price of 円1,560.00 (17.7% above fair value)
Industry Position: 37.3% below the Medical Distribution median (#69 of 111)
No single metric tells the full story. See the TSE:3151 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vital KSK Holdings Inc engaged in the wholesale and retail of pharmaceutical products. It operates through the Pharmaceutical Wholesale and Other segments. The Pharmaceutical Wholesale segment sells medicines, diagnostics, and medical devices to hospitals, medical institutions, and health practitioners. The Other segment includes retail of pharmaceutical products, wholesale of agrochemical and veterinary drugs, transportation, nursing care services, and medical consultancies. All the business activity of the group is primarily functioned through Japan and distributes its product within the Korean and to overseas market.
70GF Score
Get the complete analysis for TSE:3151
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3151 has been successfully added to your 
